Tricaprilin in Mild to Moderate Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

November 4, 2004

Primary Completion Date

June 29, 2006

Study Completion Date

January 7, 2007

Conditions
Alzheimer's Disease
Interventions
DRUG

Tricaprilin

Powder formulation will be mixed in a liquid (approximately 8 oz).

OTHER

Placebo

Powder formulation will be mixed in a liquid (approximately 8 oz).

Trial Locations (25)

27609

Multi-Specialty Research Associates of North Carolina, Raleigh

32935

Comprehensive NeuroScience, Melbourne

33021

Sunrise Clinical Research, Hollywood

33154

Baumel-Eisner Neuromedical Institute, Miami Beach

33321

Baumel-Eisner Neuromedical Institute, Inc., Fort Lauderdale

33486

Baumel-Eisner Neuromedical Institute, Boca Raton

33609

Meridien Research, Tampa

33702

Comprehensive NeuroScience, St. Petersburg

33709

Meridien Research, St. Petersburg

34102

Anchor Research Center, Naples

34471

Renstar Medical Research, Ocala

34613

Meridien Research, Brooksville

60610

Radiant Research, Chicago

75231

Radiant Research, Dallas

75234

Research Across America, Dallas

76309

Grayline Clinical Drug Trials, Wichita Falls

78229

Radiant Research, San Antonio

85013

21st Century Neurology, a division of Xenoscience Inc., Phoenix

90703

Comprehensive NeuroScience, Cerritos

90720

Pharmacology Research Institute, Los Alamitos

91324

Pharmacology Research Institute, Northridge

92270

The Southwest Institute for Clinical Research, Rancho Mirage

92506

Pharmacology Research Institute, Riverside

92660

Pharmacology Research Institute, Newport Beach

97239

Radiant Research, Portland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cerecin

INDUSTRY

NCT00142805 - Tricaprilin in Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter